论文部分内容阅读
目的探讨西妥昔单抗与胰岛素样生长因子-Ⅰ受体(IGF-ⅠR)抑制剂aIR3对人肝癌细胞株HepG2细胞的作用。方法选用浓度递增的西妥昔单抗(5~500)mg/mL和aIR3(2.5～250.0)μmol/L,单独或联合作用于HepG2细胞,观察不同时间对细胞增殖的抑制作用以及联用时的两药协同系数。结果单药西妥昔单抗与aIR3对HepG2细胞增殖的抑制作用均呈浓度依赖性与时间依赖性,二药单独作用于HepG2细胞72 h最大抑制率分别为42.2%、82.3%,二药联合作用于HepG2细胞72 h最大抑制率达91.8%。西妥昔单抗与аIR3不同浓度在各时间点的协同系数均小于1。结论西妥昔单抗和aIR3在体外对HepG2细胞的增殖均具有一定的抑制作用,联合应用时具有明显的协同效应。
Objective To investigate the effect of cetuximab and aIR3, an inhibitor of insulin-like growth factor-I receptor (IGF-ⅠR), on human hepatocellular carcinoma cell line HepG2. Methods Cetuximab (5 ~ 500) mg / mL and aIR3 (2.5 ~ 250.0) μmol / L were used singly or in combination with HepG2 cells to observe the inhibitory effect on cell proliferation at different time points Synergistic coefficient of two drugs. Results The inhibitory effects of monotherapy with cetuximab and aIR3 on HepG2 cells both in a concentration-dependent manner and in a time-dependent manner. The maximum inhibition rates of HepG2 cells treated with two drugs at 72 h were 42.2% and 82.3%, respectively The maximum inhibitory rate of 72.8 hours on HepG2 cells was 91.8%. The synergistic coefficients of cetuximab and аIR3 at different time points were all less than 1. Conclusion Both cetuximab and aIR3 can inhibit the proliferation of HepG2 cells in vitro, and have a synergistic effect when used in combination.